Hints and tips:
Related Special Reports
...“Like consumer and business audiences, authentic credibility has overtaken hard sales when it comes to increasing trust and business growth,” he added....
...BioNTech said it was aware of the lawsuit and that it would not comment on “legal strategy”....
...In legal cases being run simultaneously across Europe and the US, Moderna is not seeking to stop the use of the BioNTech/Pfizer vaccine but it wants judges to declare its patents have been infringed and...
...But, 10 years this month after Pfizer arrived on the scene, the Frenchman has a fresh challenge: persuading investors that AstraZeneca’s best days are not behind it....
...Pfizer reported dwindling Covid-19 revenues and weak sales from other products on Tuesday, as it notched a steep drop in sales in 2023....
...When it released third-quarter earnings in October, Pfizer said it expected 2023 revenues to fall to between $58bn and $61bn....
...It’s a drug that’s active against [resistant] pathogens that gives us a tool to treat the type of infection that we don’t have good options for now,” said Jay Purdy, Pfizer’s vice-president of global medical...
...Data on Pfizer’s once-daily oral pill is expected in the first half of 2024. Its shares fell 4.3 per cent lower before the open in New York. Read more on Pfizer here...
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...When it released third-quarter earnings in October, Pfizer said it expected 2023 revenues to fall to between $58bn and $61bn, down from a previously issued guidance, in May this year, of $67bn to $71bn....
...That prompted Shionogi in late October to upgrade its annual guidance for domestic sales of Xocova, while it lowered its target for international sales....
...Pfizer is abandoning its plans for a weight loss pill to be taken twice a day after trials showed it caused significant side effects, in a setback to the US drugmaker’s effort to enter the fast-growing market...
...Pfizer paid for $789,495 of “additional security protection” for its chief executive Albert Bourla, citing “heightened security risks including threats made against our executives”....
...Earlier this month, Pfizer lowered its full year revenue forecast, partly due to the US government returning about $4.2bn of its Paxlovid Covid-19 treatment....
...Pfizer revised its full-year revenue guidance to a range between $58bn and $61bn, down from $67bn-$70bn, “solely due to Covid products”, it said....
...from Pfizer and Moderna....
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...Moderna alleges that Pfizer and BioNTech infringed on two of its patents in their use of the critical mRNA platform. BioNTech and Pfizer say the patents are invalid....
...Haleon was born as a joint venture between Pfizer and GSK in 2019 that sat within GSK, before it was spun off via a UK listing in 2022, leaving GSK and Pfizer with 13.5 per cent and 32 per cent of the business...
...Pfizer’s revenue more than halved in the second quarter, after demand for its Covid-19 products fell sharply....
...GSK is expected to achieve blockbuster status for its months-old RSV vaccine this week, stealing a march on rival Pfizer and begin allaying long-standing investor concerns about its pipeline....
...The maker of Panadol painkillers, which was spun off from GSK and Pfizer in 2022, said it expected organic revenue growth of 4-6 per cent in 2024, ahead of analyst estimates of 4.5 per cent....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Pfizer said it would continue testing an alternative oral obesity drug called danuglipron, which has not raised similar concerns during clinical trials....
International Edition